Related Experiment Video
Updated: Aug 24, 2025
08:48
Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
Published on: February 16, 2022
3.0K
Anti-SARS-CoV-2 antibody immunoreactivity profiles during COVID-19 recurrence
Maria da Penha Gomes Gouvea1, Isac Ribeiro Moulaz2, Thayná Martins Gouveia2
1Universidade Federal do Espírito Santo, Hospital Universitário Cassiano Antonio Moraes, Vitória, ES, Brasil.
Revista Da Sociedade Brasileira De Medicina Tropical
|October 26, 2022
Summary
Low antibody levels may predict COVID-19 recurrence. This study found that undetectable nucleocapsid IgM and IgG antibodies correlated with symptomatic SARS-CoV-2 recurrence in healthcare workers.
Area of Science:
- Immunology
- Infectious Diseases
- Virology
Background:
- COVID-19 recurrence presents a challenge in understanding long-term immunity.
- Evaluating antibody responses is crucial for predicting disease patterns.
Purpose of the Study:
- To assess immunoglobulin G (IgG) and M (IgM) levels in healthcare workers experiencing COVID-19 recurrence.
- To investigate the correlation between antibody status and symptomatic SARS-CoV-2 recurrence.
Main Methods:
- Serum antibody levels (IgM and IgG against SARS-CoV-2 nucleocapsid) and clinical data were analyzed.
- 73 healthcare workers were divided into seroconverted (n=51) and non-seroconverted (n=22) groups.
- Anti-nucleocapsid antibodies were measured; anti-spike IgG confirmed non-seroconversion.
Main Results:
- Four cases of COVID-19 recurrence exhibited mild symptoms.
- These recurrent cases were non-seroconverted prior to symptom recurrence.
- Undetectable anti-nucleocapsid IgM and IgG were observed in recurrent cases.
Conclusions:
- Absence of anti-nucleocapsid IgM and IgG antibodies may be linked to symptomatic COVID-19 recurrence.
- Further research is needed to confirm the predictive value of antibody levels for SARS-CoV-2 recurrence.
